Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 3, 2010, Pages 334-341

  Ito, Masako ^b   Sone, Teruki ^a   Fukunaga, Masao ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Bisphosphonate; Hip geometry; Minodronic acid hydrate; Osteoporosis

Indexed keywords

MINODRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CLINICAL TRIAL; COMPRESSIVE STRENGTH; CORTICAL BONE; DRUG RESPONSE; ELASTICITY; FEMALE; FEMUR; GEOMETRY; HIP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; AGED; ALGORITHM; BLOOD; BODY MASS; BONE; BONE REMODELING; CHEMISTRY; DRUG EFFECT; HISTOLOGY; LUMBAR VERTEBRA; MIDDLE AGED; PHOTON ABSORPTIOMETRY; TIME; URINE;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; FEMUR; HIP; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 77956045886     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0138-7     Document Type: Article

References (27)

1. Yoshikawa T, Turner CH, Peacock M, Slemenda CW, Weaver CM, Teegarden D, Markwardt P, Burr DB (1994) Geometric structure of the femoral neck measured using dual-energy X-ray absorptiometry. J Bone Miner Res 9:1053-1064
2. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU (1990) Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol 25:6-18
3. Ahlborg HG, Nguyen ND, Nguyen TV, Center JR, Eisman JA (2005) Contribution of hip strength indices to hip fracture risk in elderly men and women. J Bone Miner Res 20:1820-1827
4. Rivadeneira F, Zillikens MC, De Leat CE, Hofman A, Uitterlinden AG, Beck TJ, Pols HA (2007) Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam study. J Bone Miner Res 22:1781-1790
5. Kaptoge S, Beck TJ, Reeve J, Stone KL, Hiller TA, Cauley JA, Cummings SR (2008) Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 23:1892-1904
6. Mayhew P, Kaptoge S, Loveridge N, Power J, Kroger HP, Parker M, Reeve J (2004) Discrimination between cases of hip fracture and controls is improved by hip structural analysis compared to areal bone mineral density. An ex vivo study of the femoral neck. Bone (NY) 34:352-361
7. Mori H, Kayasuga R, Tanaka M, Kawabata K, Nozaki K, Mori M, Sasamata M (2008) Inhibitory effect of minodronic acid on bone resorption in vitro and in vivo. Clin Pharmacol Ther 18:S19-S32
8. Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K (2008) Long-term minodronic acid (ONO-5920/ YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone (NY) 43:894-900
9. Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T (2008) Minodronic acid (ONO- 5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone (NY) 43:840-848
10. Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone (NY) 44:1078-1084
11. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20(8):1429-1437
12. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y, The Committee of the Japanese Society for Bone and Mineral Research for Development of Diagnosis Criteria of Osteoporosis (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139-150
13. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
14. Martin RB, Burr DB (1984) Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry. J Biomech 17:195-201
15. Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5:49-55
16. Beck T (2003) Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 14:S81-S88
17. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, doubleblind, placebo-controlled clinical trial. J Bone Miner Res 20:1525-1532
18. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE (2009) DXA-based hip structural analysis of onceweekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911-921
19. Beck TJ, Stone KL, Oreskovic TL, Hochberg MC, Nevitt MC, Genant HK, Cummings SR (2001) Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J Bone Miner Res 16:2103-2110
20. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1- 34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone (NY) 36:948-958
21. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575-586
22. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351-359
23. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, for the Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 19:1250-1258
24. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
25. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
26. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
27. Takada J, Beck TJ, Miki T, Imanishi Y, Nakatsuka K, Wada H, Naka H, Iba K, Yoshizaki T, Yamashita T (2008) Hip structure analysis for raloxifene treatment in Japanese women with osteoporosis. J Bone Miner Res 23(Suppl 1):S211